Our coordinator Holm Graessner is participating in the Brain Innovation Days’ Platinum Panel “Advancing Adaptive Pathways and Real-World Evidence for Orphan Drugs” on October 15th, 11:55 CEST.
This session will explore how adaptive pathways and Real-World Evidence (RWE), including patient-experienced data, can be more effectively integrated into policy frameworks to improve access to innovative treatments for rare brain disorders. With patients often facing long delays and limited options, there is a growing need to rethink how we evaluate and approve therapies. In partnership with Merck KGaA Healthcare, this session will bring together stakeholders from across the healthcare ecosystem and aims to identify collaborative, patient-centred policy solutions that accelerate access while ensuring long-term sustainability and equity.
Find the whole programme here.
